VEGFA and neoplasm: In osteosarcoma cells, CBMC combined with apatinib significantly inhibited tumor growth in an OS nude mouse model, attenuated weight loss due to tumor growth, and reduced VEGF and Bc1–2 expression in a dose-dependent manner.